Development of myasthenia gravis in a patient with chronic myeloid leukemia during treatment with nilotinib
| Autor: | Maria MacDonald, Michael W. Nicolle, David Sanford, Anargyros Xenocostas |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Autoimmune disease
chronic myeloid leukemia tyrosine kinase inhibitors adverse drug events lcsh:RC633-647.5 business.industry Myeloid leukemia Case Report lcsh:Diseases of the blood and blood-forming organs Hematology Kinase inhibition medicine.disease Myasthenia gravis Nilotinib chronic myeloid leukemia hemic and lymphatic diseases tyrosine kinase inhibitors Immunology adverse drug events Medicine business Adverse effect Tyrosine kinase medicine.drug |
| Zdroj: | Hematology Reports Hematology Reports, Vol 6, Iss 2 (2014) |
| ISSN: | 2038-8330 2038-8322 |
| Popis: | We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well as the use of tyrosine kinase inhibitors. Second generation tyrosine kinase inhibitors are highly effective in the treatment of CML, although can result in adverse effects related to off-target kinase inhibition, and longer term reporting of adverse effects is required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|